Advertisement

Topics

Bioniche Therapeutics Company Profile

12:33 EST 20th November 2017 | BioPortfolio

I'm pleased to welcome you to the Bioniche Life Sciences website. We hope your visit provides you with an informative view of the company, our goals, our science and our focus on innovation. In 2004, Bioniche achieved an important milestone: our 25th year in business. Today, we have an expanding global presence, a dedicated employee base, an experienced leadership team, and a product and technology mix that is exceptional

Location

P.O. Box 1570
Belleville,
Ontario
K8N 5J2
Canada

Contact

Phone: 613) 966-8058 or (800) 265-5464
Fax: (613) 966-4177
Email: rlevine@hfgcg.com


News Articles [527 Associated News Articles listed on BioPortfolio]

Bioniche: Graeme McRae on Bioniche`s Newly Discovered Cancer Killing Bacteria

In this episode of PharmaTelevision News Review, Fintan Walton talks with Graeme McRae, CEO at Bioniche. Filmed at BioChicago 2010 in Chicago, USA, they discuss: • Origins and focus of Bioniche •...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Deals this week: Nabriva Therapeutics, LifeMine Therapeutics, Aldeyra Therapeutics

Nabriva Therapeutics plans to raise $80m through an underwritten public offering of shares of its common stock.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, ...

http://dailystocktracker.com/register/ Cytori Therapeutics San Diego, Californiaheadquartered Cytori Therapeutics Inc.'s shares dropped 2.15%, closing Monday's trading session at $0.39. The stock ...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

SMi Group announces the 9th Annual RNA Therapeutics Conference

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towar...

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

Clinical Trials [120 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1173 Associated Companies listed on BioPortfolio]

Bioniche Therapeutics

I'm pleased to welcome you to the Bioniche Life Sciences website. We hope your visit provides you with an informative view of the company, our goals, our science and our focus on innovation. In 2004, ...

Bioniche Pharma

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, including anaesthesiology, orthopedics, rheumatology, urology, and dermatology. An in...

Bioniche Animal Health USA, Inc.

Bioniche Animal Health was formed in 1979 as a privately owned company to develop vaccines and other pharmaceutical-based products for the preventative health management of animal diseases. Now a Divi...

Bioniche Inc

Bioniche Life Sciences Inc. is a fully integrated, Canadian biopharmaceutical company engaged in the research, development, production and commercialization of proprietary technologies for human and a...

Bioniche Life Sciences Inc.

More Information about "Bioniche Therapeutics" on BioPortfolio

We have published hundreds of Bioniche Therapeutics news stories on BioPortfolio along with dozens of Bioniche Therapeutics Clinical Trials and PubMed Articles about Bioniche Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bioniche Therapeutics Companies in our database. You can also find out about relevant Bioniche Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record